^
    5d
    Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544 (clinicaltrials.gov)
    P1, N=16, Recruiting, Pfizer
    New P1 trial
    |
    claturafenib (PF-07799933) • polfurmetinib (PF-07799544)
    17d
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (clinicaltrials.gov)
    P1, N=267, Recruiting, Pfizer | Trial completion date: May 2030 --> Aug 2030 | Trial primary completion date: Nov 2028 --> Feb 2029
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    BRAF V600E • MSI-H/dMMR
    |
    Erbitux (cetuximab) • 5-fluorouracil • Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • claturafenib (PF-07799933) • midazolam hydrochloride
    5ms
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (clinicaltrials.gov)
    P1, N=267, Recruiting, Pfizer | N=156 --> 267 | Trial completion date: Sep 2028 --> Apr 2030 | Trial primary completion date: Mar 2027 --> Oct 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    Erbitux (cetuximab) • 5-fluorouracil • Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • claturafenib (PF-07799933) • midazolam hydrochloride
    7ms
    C4901001: A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=124, Recruiting, Pfizer | Trial completion date: Apr 2029 --> Oct 2028 | Trial primary completion date: Oct 2027 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib) • claturafenib (PF-07799933) • polfurmetinib (PF-07799544)
    1year
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (clinicaltrials.gov)
    P1, N=156, Recruiting, Pfizer | Trial completion date: Mar 2028 --> Aug 2028 | Trial primary completion date: Sep 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • claturafenib (PF-07799933)
    1year
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (clinicaltrials.gov)
    P1, N=156, Recruiting, Pfizer | Trial completion date: Dec 2027 --> Mar 2028 | Trial primary completion date: Jun 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • claturafenib (PF-07799933)
    over1year
    C4901001: A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=124, Recruiting, Pfizer | Trial completion date: Sep 2028 --> Aug 2029 | Trial primary completion date: Mar 2027 --> Feb 2028
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib) • claturafenib (PF-07799933) • polfurmetinib (PF-07799544)
    over1year
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (clinicaltrials.gov)
    P1, N=156, Recruiting, Pfizer | Trial completion date: Feb 2029 --> Nov 2027 | Trial primary completion date: Aug 2027 --> May 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • claturafenib (PF-07799933)
    almost2years
    A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=124, Recruiting, Pfizer | Trial completion date: Mar 2027 --> Sep 2028 | Trial primary completion date: Oct 2025 --> Mar 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Braftovi (encorafenib) • claturafenib (PF-07799933) • polfurmetinib (PF-07799544)
    2years
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (clinicaltrials.gov)
    P1, N=174, Recruiting, Pfizer | Trial completion date: May 2027 --> Dec 2028 | Trial primary completion date: Nov 2025 --> Jun 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • claturafenib (PF-07799933)
    2years
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (clinicaltrials.gov)
    P1, N=174, Recruiting, Pfizer | Trial completion date: Feb 2028 --> May 2027
    Trial completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • claturafenib (PF-07799933)
    over2years
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=174, Recruiting, Pfizer | Trial completion date: Apr 2027 --> Feb 2028
    Trial completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • claturafenib (PF-07799933)